MA54868A - Arn thérapeutique contre le cancer de la prostate - Google Patents
Arn thérapeutique contre le cancer de la prostateInfo
- Publication number
- MA54868A MA54868A MA054868A MA54868A MA54868A MA 54868 A MA54868 A MA 54868A MA 054868 A MA054868 A MA 054868A MA 54868 A MA54868 A MA 54868A MA 54868 A MA54868 A MA 54868A
- Authority
- MA
- Morocco
- Prior art keywords
- prostate cancer
- against prostate
- therapeutic against
- rna therapeutic
- rna
- Prior art date
Links
- 206010060862 Prostate cancer Diseases 0.000 title 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001158—Proteinases
- A61K39/00116—Serine proteases, e.g. kallikrein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/884—Vaccine for a specifically defined cancer prostate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2019056185 | 2019-03-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA54868A true MA54868A (fr) | 2021-12-08 |
Family
ID=69743256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA054868A MA54868A (fr) | 2019-03-12 | 2020-03-11 | Arn thérapeutique contre le cancer de la prostate |
Country Status (17)
Country | Link |
---|---|
US (1) | US20230114808A1 (fr) |
EP (1) | EP3917562A1 (fr) |
JP (1) | JP2022525103A (fr) |
KR (1) | KR20210138586A (fr) |
CN (1) | CN113710267A (fr) |
AU (1) | AU2020233995A1 (fr) |
BR (1) | BR112021018039A2 (fr) |
CA (1) | CA3132908A1 (fr) |
CL (1) | CL2021002359A1 (fr) |
CO (1) | CO2021011892A2 (fr) |
CU (1) | CU20210075A7 (fr) |
IL (1) | IL285961A (fr) |
MA (1) | MA54868A (fr) |
MX (1) | MX2021010862A (fr) |
SG (1) | SG11202108691TA (fr) |
WO (1) | WO2020182869A1 (fr) |
ZA (1) | ZA202106392B (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112501201A (zh) * | 2021-02-07 | 2021-03-16 | 无锡市人民医院 | 一种用于治疗非小细胞肺癌的rna疫苗及其构建方法 |
WO2023030635A1 (fr) * | 2021-09-02 | 2023-03-09 | BioNTech SE | Test d'activité pour potentiel thérapeutique d'acide nucléique codant |
KR20230144421A (ko) * | 2022-04-07 | 2023-10-16 | 엠큐렉스 주식회사 | 사스-코로나바이러스 2 감염증에 대한 rna 백신 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2324055A2 (fr) | 2008-08-25 | 2011-05-25 | Amplimmune, Inc. | Polypeptides cibles co-stimulateurs et methodes pour le traitement du cancer |
JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Pd−l1/pd−l2の同時阻害 |
WO2013143555A1 (fr) | 2012-03-26 | 2013-10-03 | Biontech Ag | Formulation d'arn pour immunothérapie |
JP2016532451A (ja) * | 2013-08-21 | 2016-10-20 | キュアバック アーゲー | 前立腺癌処置のための組成物およびワクチン |
WO2016005004A1 (fr) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilisation de séquences d'adn codant pour une séquence poly (a) |
EP3777881A1 (fr) * | 2016-04-22 | 2021-02-17 | CureVac AG | Arn codant pour un antigène tumoral |
-
2020
- 2020-03-11 CN CN202080013878.2A patent/CN113710267A/zh active Pending
- 2020-03-11 MX MX2021010862A patent/MX2021010862A/es unknown
- 2020-03-11 US US17/310,773 patent/US20230114808A1/en active Pending
- 2020-03-11 WO PCT/EP2020/056476 patent/WO2020182869A1/fr active Application Filing
- 2020-03-11 CA CA3132908A patent/CA3132908A1/fr active Pending
- 2020-03-11 AU AU2020233995A patent/AU2020233995A1/en active Pending
- 2020-03-11 JP JP2021554703A patent/JP2022525103A/ja active Pending
- 2020-03-11 BR BR112021018039A patent/BR112021018039A2/pt unknown
- 2020-03-11 SG SG11202108691TA patent/SG11202108691TA/en unknown
- 2020-03-11 MA MA054868A patent/MA54868A/fr unknown
- 2020-03-11 CU CU2021000075A patent/CU20210075A7/es unknown
- 2020-03-11 EP EP20709210.7A patent/EP3917562A1/fr active Pending
- 2020-03-11 KR KR1020217027838A patent/KR20210138586A/ko unknown
-
2021
- 2021-08-30 IL IL285961A patent/IL285961A/en unknown
- 2021-09-01 ZA ZA2021/06392A patent/ZA202106392B/en unknown
- 2021-09-09 CL CL2021002359A patent/CL2021002359A1/es unknown
- 2021-09-10 CO CONC2021/0011892A patent/CO2021011892A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP3917562A1 (fr) | 2021-12-08 |
ZA202106392B (en) | 2023-06-28 |
AU2020233995A1 (en) | 2021-09-23 |
BR112021018039A2 (pt) | 2021-11-23 |
KR20210138586A (ko) | 2021-11-19 |
MX2021010862A (es) | 2021-10-22 |
CA3132908A1 (fr) | 2020-09-17 |
US20230114808A1 (en) | 2023-04-13 |
CN113710267A (zh) | 2021-11-26 |
JP2022525103A (ja) | 2022-05-11 |
CO2021011892A2 (es) | 2022-01-28 |
CU20210075A7 (es) | 2022-04-07 |
SG11202108691TA (en) | 2021-09-29 |
WO2020182869A1 (fr) | 2020-09-17 |
IL285961A (en) | 2021-10-31 |
CL2021002359A1 (es) | 2022-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA54192A (fr) | Vaccins à arn contre le cancer | |
SG10201913631TA (en) | Rna for cancer therapy | |
EP3368656A4 (fr) | Thérapie anticancéreuse ciblée | |
EP3576751A4 (fr) | Vaccins anticancéreux à arn | |
MA47680A (fr) | Arn thérapeutique | |
EP3651772A4 (fr) | Polythérapie anticancéreuse | |
ZA202005847B (en) | Cancer therapy | |
EP3413927A4 (fr) | Cancérothérapie | |
MA54868A (fr) | Arn thérapeutique contre le cancer de la prostate | |
MA48728A (fr) | Polythérapie contre le cancer de la prostate | |
EP3383407A4 (fr) | Conjugués de cytarabine pour le traitement du cancer | |
EP3787612A4 (fr) | Traitements du cancer ciblant des cellules souches cancéreuses | |
EP3733175A4 (fr) | Traitement du cancer | |
EP3568694A4 (fr) | Nanoconjugués de doxorubicine-or ciblés pour la thérapie antitumorale | |
GB201905780D0 (en) | Cancer therapy | |
EP3796891A4 (fr) | Constructions thérapeutiques pour le traitement du cancer | |
EP3713576A4 (fr) | Méthodes de traitement du cancer | |
EP3576746A4 (fr) | Traitement du cancer | |
EP3256115A4 (fr) | Polythérapie anticancéreuse | |
EP3675891A4 (fr) | Polythérapie anticancéreuse | |
IL284646A (en) | Therapeutic RNA for the treatment of solid cancer tumors in advanced stages | |
EP3532638A4 (fr) | Ciblage de microarn-101-3 p dans une cancérothérapie | |
EP3423581A4 (fr) | Ciblage de micro-arn pour le traitement du cancer | |
MA54932A (fr) | Traitement contre le cancer | |
GB201913957D0 (en) | Cancer |